DENTSPLY SIRONA (XRAY) Competitors

$30.18
+0.17 (+0.57%)
(As of 05/1/2024 ET)

XRAY vs. NVST, IONS, ACHC, PCVX, RVMD, ELAN, APLS, ENSG, HQY, and CYTK

Should you be buying DENTSPLY SIRONA stock or one of its competitors? The main competitors of DENTSPLY SIRONA include Envista (NVST), Ionis Pharmaceuticals (IONS), Acadia Healthcare (ACHC), Vaxcyte (PCVX), Revolution Medicines (RVMD), Elanco Animal Health (ELAN), Apellis Pharmaceuticals (APLS), The Ensign Group (ENSG), HealthEquity (HQY), and Cytokinetics (CYTK). These companies are all part of the "medical" sector.

DENTSPLY SIRONA vs.

DENTSPLY SIRONA (NASDAQ:XRAY) and Envista (NYSE:NVST) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, community ranking, dividends, profitability and media sentiment.

DENTSPLY SIRONA has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500. Comparatively, Envista has a beta of 1.35, indicating that its share price is 35% more volatile than the S&P 500.

95.7% of DENTSPLY SIRONA shares are held by institutional investors. 0.5% of DENTSPLY SIRONA shares are held by insiders. Comparatively, 1.3% of Envista shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

DENTSPLY SIRONA has a net margin of -3.33% compared to Envista's net margin of -3.90%. DENTSPLY SIRONA's return on equity of 11.14% beat Envista's return on equity.

Company Net Margins Return on Equity Return on Assets
DENTSPLY SIRONA-3.33% 11.14% 5.22%
Envista -3.90%6.31%4.07%

DENTSPLY SIRONA received 426 more outperform votes than Envista when rated by MarketBeat users. Likewise, 61.38% of users gave DENTSPLY SIRONA an outperform vote while only 40.30% of users gave Envista an outperform vote.

CompanyUnderperformOutperform
DENTSPLY SIRONAOutperform Votes
453
61.38%
Underperform Votes
285
38.62%
EnvistaOutperform Votes
27
40.30%
Underperform Votes
40
59.70%

Envista has lower revenue, but higher earnings than DENTSPLY SIRONA. DENTSPLY SIRONA is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DENTSPLY SIRONA$3.97B1.58-$132M-$0.62-48.85
Envista$2.57B1.33-$100.20M-$0.61-32.56

In the previous week, DENTSPLY SIRONA had 1 more articles in the media than Envista. MarketBeat recorded 8 mentions for DENTSPLY SIRONA and 7 mentions for Envista. DENTSPLY SIRONA's average media sentiment score of 0.75 beat Envista's score of 0.59 indicating that DENTSPLY SIRONA is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
DENTSPLY SIRONA
5 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Envista
3 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

DENTSPLY SIRONA presently has a consensus target price of $39.50, suggesting a potential upside of 30.36%. Envista has a consensus target price of $27.90, suggesting a potential upside of 41.55%. Given Envista's higher probable upside, analysts clearly believe Envista is more favorable than DENTSPLY SIRONA.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DENTSPLY SIRONA
0 Sell rating(s)
3 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.67
Envista
3 Sell rating(s)
6 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
1.91

Summary

DENTSPLY SIRONA beats Envista on 12 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XRAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

XRAY vs. The Competition

MetricDENTSPLY SIRONADental equipment & supplies IndustryMedical SectorNASDAQ Exchange
Market Cap$6.28B$1.27B$4.88B$7.44B
Dividend Yield2.09%1.13%2.81%3.95%
P/E Ratio-48.856.73193.5515.99
Price / Sales1.580.592,465.5185.40
Price / Cash6.3613.1846.4935.50
Price / Book1.951.174.734.25
Net Income-$132M-$36.51M$102.52M$213.95M
7 Day Performance-2.04%-2.27%1.33%0.09%
1 Month Performance-6.08%-11.99%-6.01%-5.38%
1 Year Performance-28.54%-29.70%4.45%5.93%

DENTSPLY SIRONA Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NVST
Envista
4.6003 of 5 stars
$20.23
+0.6%
$29.60
+46.4%
-48.9%$3.48B$2.57B-33.1612,800News Coverage
IONS
Ionis Pharmaceuticals
4.1009 of 5 stars
$41.84
+1.9%
$56.08
+34.0%
+16.7%$6.10B$788M-16.34927
ACHC
Acadia Healthcare
4.8309 of 5 stars
$70.74
+0.7%
$94.75
+33.9%
+2.3%$6.54B$2.93B-282.9523,500Short Interest ↓
PCVX
Vaxcyte
1.0658 of 5 stars
$60.88
-1.2%
$78.50
+28.9%
+41.4%$6.62BN/A-14.74254Positive News
RVMD
Revolution Medicines
3.5092 of 5 stars
$36.26
-0.5%
$41.20
+13.6%
+58.7%$5.97B$11.58M-9.62378Positive News
ELAN
Elanco Animal Health
3.8579 of 5 stars
$13.45
+4.0%
$16.71
+24.3%
+39.0%$6.63B$4.42B-5.389,300Upcoming Earnings
Short Interest ↑
APLS
Apellis Pharmaceuticals
4.3831 of 5 stars
$48.72
+2.3%
$77.93
+60.0%
-47.0%$5.87B$396.59M-10.87702Upcoming Earnings
Analyst Report
Options Volume
News Coverage
ENSG
The Ensign Group
4.1374 of 5 stars
$118.62
+1.2%
$119.20
+0.5%
+21.9%$6.75B$3.73B32.4135,300News Coverage
HQY
HealthEquity
3.6804 of 5 stars
$79.87
-1.6%
$96.17
+20.4%
+47.6%$6.85B$999.59M124.803,150Positive News
CYTK
Cytokinetics
4.0851 of 5 stars
$65.57
-1.1%
$79.33
+21.0%
+64.0%$6.86B$7.53M-12.03423Upcoming Earnings
Short Interest ↑

Related Companies and Tools

This page (NASDAQ:XRAY) was last updated on 5/1/2024 by MarketBeat.com Staff

From Our Partners